PCRX

The most significant stock event in the past six months was the definitive agreement for Viatris Inc. to acquire Pacira BioSciences for $36.50 per share in cash, totaling an aggregate equity value of $1.65 billion, announced on October 8, 2026. This news caused Pacira shares to surge by approximately 44% to $36.28, nearing its 52-week high, with the deal anticipated to close by the end of 2026. Prior to the acquisition announcement, analyst ratings varied, with Oppenheimer, Jefferies, and Needham downgrading Pacira to a 'Hold' rating on October 8, 2026, while Truist Financial had raised its price target to $31 and maintained a 'Buy' rating on October 7, 2026. The company's latest quarterly results exceeded expectations, reporting an EPS of $0.73 against a $0.65 consensus estimate and revenue of $192.4 million, up 6.2% year-over-year. In the first quarter of 2026, EXPAREL revenue increased by 5%, ZILRETTA revenue by 15%, and iovera° revenue by 21% year-over-year. A class action lawsuit was filed on behalf of investors who purchased Pacira securities between August 2, 2023, and August 8, 2024, alleging insufficient patent protections on Exparel and misleading statements.